We advised the representatives of the initial purchasers on the offering

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by Ionis Pharmaceuticals, Inc. of an aggregate principal amount of $770 million of its 0.00% convertible senior notes due 2030, which included $70 million aggregate principal amount of notes sold pursuant to the exercise in full of the initial purchasers’ option.

For three decades as a pioneer in RNA-targeted medicines, Ionis Pharmaceuticals has focused on bringing better futures to people with serious diseases. Ionis Pharmaceuticals is headquartered in Carlsbad, California.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Savannah J. Dowling and Matthew Franklin. The intellectual property team included partner David R. Bauer and associates Jordan Khorshad and Bari Britvan. The tax team included partner Aliza Slansky and associate Bradford Sherman. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post